Rallybio Corporation RLYB
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -4.50% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -4.50% | |||
| Cost of Revenue | -40.36% | -65.23% | |||
| Gross Profit | 28.42% | 69.15% | |||
| SG&A Expenses | -8.88% | 80.33% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -14.90% | 0.14% | |||
| Operating Income | 12.10% | -0.30% | |||
| Income Before Tax | 643.48% | -41.46% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 627.48% | -41.46% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 627.48% | -41.46% | |||
| EBIT | 12.10% | -0.30% | |||
| EBITDA | 12.09% | -0.30% | |||
| EPS Basic | 626.50% | -41.31% | |||
| Normalized Basic EPS | 851.42% | -2.02% | |||
| EPS Diluted | 617.45% | -41.31% | |||
| Normalized Diluted EPS | 838.61% | -2.02% | |||
| Average Basic Shares Outstanding | 0.18% | 0.10% | |||
| Average Diluted Shares Outstanding | 1.92% | 0.10% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||